Pyxis Oncology (PYXS) EBITDA Margin (2024 - 2025)
Pyxis Oncology (PYXS) reported EBITDA Margin of 164.18% for Q4 2025, up 74.85% quarter-over-quarter from 652.77% in Q2 2025.
Pyxis Oncology (PYXS) EBITDA Margin (2024 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 2 years of EBITDA Margin data on file, last reported at 164.18% in Q4 2025.
- EBITDA Margin for Q4 2025 came in at 164.18%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 575.39% (down 9711.0% YoY), and the FY2025 annual result was 575.39%, down 9711.0% from the prior year.
- EBITDA Margin advanced to 164.18% in Q4 2025 per PYXS's latest filing, from 652.77% in the prior quarter.
- Over five years, EBITDA Margin peaked at 20.93% in Q1 2024 and troughed at 652.77% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -164.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -164.18% |
| Jun 30, 2025 | -652.77% |
| Mar 31, 2024 | -20.93% |